A Look At Fresenius Medical Care (XTRA:FME) Valuation After Its Newly Announced Annual Dividend

Dividend announcement and buyback activity draw investor focus

Fresenius Medical Care (XTRA:FME) recently announced an annual dividend of €1.49 per share, payable on 27 May 2026, with an ex dividend date of 22 May and record date of 25 May.

Alongside the dividend details, the company is updating investors on a second tranche of its ongoing share buyback program, which recently included the repurchase of 553,500 shares.

See our latest analysis for Fresenius Medical Care.

Fresenius Medical Care’s €40.34 share price has seen a 4.32% 7 day share price return and a 2.13% 90 day share price return, while the 1 year total shareholder return is close to flat. This suggests momentum is steady rather than accelerating.

If you are looking beyond Fresenius Medical Care in the broader healthcare space, this could be a useful moment to scan for other dialysis and medical technology peers using a healthcare focused screener such as 123 healthcare AI stocks

With the shares close to flat over 1 year, trading at €40.34 and showing an implied discount to analyst targets and intrinsic value estimates, you have to ask whether Fresenius Medical Care is overlooked or whether the market is already pricing in future growth.

Most Popular Narrative: 9.8% Undervalued

Analysts involved in the most followed narrative see Fresenius Medical Care’s fair value at €44.71, compared with the current €40.34 share price, setting up a valuation gap that rests on specific growth and profitability assumptions.

Ongoing process automation, supply chain optimization, and disciplined portfolio management (e.g., FME25+ transformation program) are expected to deliver continuing operational efficiencies, supporting operating margin expansion and higher free cash flow, which may enable further shareholder distributions through buybacks or dividends.

Read the complete narrative.

Want to see what sits behind that efficiency push and cash flow story? The narrative focuses on steadier earnings, improving margins, and a different future profit multiple.

Result: Fair Value of €44.71 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to weigh risks such as regulatory pressure on US reimbursement and ongoing profitability challenges in the Value Based Care segment, which could upset this thesis.

Find out about the key risks to this Fresenius Medical Care narrative.

Next Steps

With the mix of dividends, buybacks and a fair value gap, sentiment around Fresenius Medical Care is clearly in focus. Move quickly, check the underlying numbers for yourself, then weigh those against the 5 key rewards

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on other opportunities that could fit your goals just as well or even better.

• Target steady income potential by scanning companies described as 479 dividend fortresses and see which yields and payout histories fit your approach.
• Hunt for quality at a sensible price using the 231 high quality undervalued stocks to spot businesses that combine solid fundamentals with appealing valuations.
• Prioritise resilience by reviewing the 298 resilient stocks with low risk scores and focus on companies with characteristics that may help smooth out portfolio volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com